NCT01593046 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Dose Administration of Long-Acting GSK1265744 and Long-Acting TMC278 Intramuscular and Subcutaneous Injections in Healthy Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

GSK1265744 Oral

30mg tablet

DRUG

GSK1265744 LAP 800mg intramuscular injection

800mg Loading dose given at month 1 dose

DRUG

GSK1265744 LAP 200mg subcutaneous injection

200mg maintenance dose give at months 2 - 4

DRUG

GSK1265744 LAP 200mg intramuscular injection

200mg maintenance dose given at months 2 - 4

DRUG

GSK1265744 LAP 400mg intramuscular injection

400mg maintenance dose given at month 2 - 4

DRUG

TMC278 LA 1200mg intramuscular injection

1200mg Loading dose given at month 3

DRUG

TMC278 LA 600mg intramuscular injection

600mg Loading dose given at month 4

DRUG

GSK1265744 LAP 800mg intramuscular injection

800mg dose given quarterly (once every) 12 weeks

Trial Locations (2)

GSK Investigational Site, Daytona Beach

GSK Investigational Site, Overland Park